GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side ...